Fulgent Genetics Quarterly Cash Flow Statement
NASDAQ: FLGTHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Fulgent Genetics free cash flow
In the quarter ended Jun 30, 2026, Fulgent Genetics generated -$23.8 million of operating cash flow and spent $3.9 million on capital expenditures. That left free cash flow of -$27.6 million, a free-cash-flow margin of -32.3% of revenue. Fulgent Genetics returned $23.8 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Fulgent Genetics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -29.72M | -25.27M | -23.65M | -6.83M | -19.26M | -11.90M | -6.19M | -14.69M | -9.09M | -13.85M | -134.33M | -13.47M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -1102.68% |
| Depreciation & Amortization | 7.68M | 6.00M | 6.11M | 6.04M | 6.05M | 5.92M | 6.19M | 5.92M | 6.15M | 6.66M | 6.53M | 6.42M |
| Stock-Based Compensation | 8.62M | 9.89M | 9.28M | 9.72M | 10.04M | 10.55M | 10.41M | 10.92M | 11.63M | 11.52M | 11.43M | 10.90M |
| Change in Working Capital | -10.00K | 18.19M | -11.30M | 3.07M | -8.47M | -3.80M | -14.09M | -445.00K | -246.00K | 1.10M | -5.71M | -13.30M |
| Operating Cash Flow | -23.76M | 7.10M | -78.14M | 11.11M | -30.17M | -4.43M | 25.02M | -15.51M | 4.29M | 7.27M | 14.93M | 10.24M |
| Capital Expenditures | -3.86M | -5.20M | -4.98M | -6.05M | -6.83M | -4.72M | -3.78M | -19.54M | -12.94M | -4.06M | -3.11M | -4.92M |
| Investing Cash Flow | 50.80M | 10.94M | 11.15M | 19.08M | 53.40M | 27.73M | -27.45M | 8.98M | 7.30M | -47.19M | 24.27M | 20.08M |
| Share Repurchases | -23.80M | -40.08M | 0 | 0 | -2.21M | -8.68M | 0 | 0 | 0 | -225.00K | -22.86M | — |
| Financing Cash Flow | -24.23M | -44.83M | -534.00K | -445.00K | -2.64M | -11.17M | -327.00K | -567.00K | -1.15M | -2.81M | -25.95M | -4.47M |
| Net Change in Cash | 2.91M | -26.79M | -67.45M | 29.76M | 20.60M | 12.14M | -2.90M | -6.93M | 10.43M | -42.80M | 13.40M | 25.73M |
| Free Cash Flow | -27.62M | 1.90M | -83.12M | 5.06M | -37.00M | -9.15M | 21.24M | -35.05M | -8.66M | 3.21M | 11.83M | 5.32M |
This table shows 12 quarterly periods of Fulgent Genetics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow FLGT's reporting calendar. What is a cash flow statement?